HALO Growth 100 · Sector S2
Longevity & Healthspan
GLP-1 leaders, gene-editing platforms, diagnostics-at-scale, biopharma compounders. Demographics writes the demand curve.
Equal-weight — 1d —
Cap-weighted — 1d —
Momentum (drift) — 1d —
Constituents — in this sector
Composite Index — since inception (Dec 30, 2025)
Three weighting variants of the same constituent basket, rebased to 1,000 at inception. EW = ticker-equal-weight with quarterly drift. CW = cap-weighted (10% cap; below ten names the cap is infeasible, so the sub-index is equal weight by construction) with semi-annual rebalance. MW = drift-only (1/N at inception, market does the tilting between rebalances). Click a legend entry to toggle its line.
Constituents
Every HALO 100 constituent tagged into this sector. Click a column header to sort (best to worst). Click a row to open the stock detail page in a new tab.
| Ticker | Company | Region | Last | 1d | 1w | 1m | 3m | 6m | 1y | CCY |
|---|---|---|---|---|---|---|---|---|---|---|
| GXI.DE | Gerresheimer | EUR | 33.00 | +5.30% | +0.86% | +26.73% | +17.10% | +34.47% | +12.24% | EUR |
| LLY | Eli Lilly | NAM | 1279.14 | +0.45% | +3.13% | +8.08% | +4.79% | +47.32% | +56.28% | USD |
| AMGN | Amgen | NAM | 444.63 | +1.22% | +4.63% | +7.24% | +13.11% | +30.70% | +53.95% | USD |
| REGN | Regeneron | NAM | 807.67 | +0.33% | +3.28% | +2.49% | +16.18% | +8.49% | +40.64% | USD |
| NVO | Novo Nordisk | EUR | 39.13 | +0.20% | +1.85% | +0.85% | -23.21% | -5.02% | -23.79% | USD |
| ILMN | Illumina | NAM | 271.04 | +0.60% | +3.19% | +0.39% | +40.45% | +110.89% | +171.12% | USD |
| VRTX | Vertex Pharma | NAM | 517.49 | -1.23% | +3.10% | -1.65% | +5.53% | +21.47% | +22.45% | USD |
| NTRA | Natera | NAM | 404.90 | +0.24% | +1.37% | -1.86% | +60.53% | +98.10% | +107.64% | USD |
| ZEAL.CO | Zealand Pharma | EUR | 223.30 | -1.19% | +0.68% | -18.12% | -26.81% | -26.33% | -52.81% | DKK |
| VKTX | Viking Therapeutics | NAM | 24.21 | -0.78% | -3.35% | -31.92% | -28.50% | -26.60% | -28.63% | USD |